Comments received from public consultation on good pharmacovigilance practices (GVP) Product- or Population-Specific Considerations III: Pregnant and breastfeeding women (EMA/653036/2019)

Guidelines on good pharmacovigilance practices (GVP): Introductory cover note, last updated with final considerations on pregnant and breastfeeding women and their children exposed in utero or via breastmilk

Guidelines on good pharmacovigilance practices (GVP): Introductory cover note, last updated with final considerations on pregnant and breastfeeding women and their children exposed in utero or via breastmilk

Guideline on good pharmacovigilance practices (GVP): Product- or population-specific considerations III: Pregnant and breastfeeding women and their children exposed in utero or via breastmilk

Archive of development of good pharmacovigilance practices

Highlights – 1st European Medicine Agency (EMA) and European Respiratory Society (ERS) bilateral meeting

Human medicines European public assessment report (EPAR): Helicobacter Test INFAI, 13C-urea, Date of authorisation: 14/08/1997, Revision: 22, Status: Authorised

Human medicines European public assessment report (EPAR): Exforge HCT, amlodipine besilate,valsartan,hydrochlorothiazide, Date of authorisation: 15/10/2009, Revision: 28, Status: Authorised

Human medicines European public assessment report (EPAR): Alymsys, bevacizumab, Date of authorisation: 26/03/2021, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Dafiro HCT, amlodipine besilate,valsartan,hydrochlorothiazide, Date of authorisation: 03/11/2009, Revision: 30, Status: Authorised